Last reviewed · How we verify
Flu-ATG — Competitive Intelligence Brief
phase 3
Polyclonal antithymocyte globulin (ATG)
T lymphocytes (CD2, CD3, CD4, CD8, and other T-cell surface antigens)
Immunology / Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Flu-ATG (Flu-ATG) — Cooperative Study Group A for Hematology. Flu-ATG is an anti-thymocyte globulin derived from immunized rabbits that depletes T lymphocytes to suppress immune-mediated rejection and autoimmune responses.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Flu-ATG TARGET | Flu-ATG | Cooperative Study Group A for Hematology | phase 3 | Polyclonal antithymocyte globulin (ATG) | T lymphocytes (CD2, CD3, CD4, CD8, and other T-cell surface antigens) | |
| Thymoglobulin (ATG) | Thymoglobulin (ATG) | M.D. Anderson Cancer Center | marketed | Polyclonal antithymocyte globulin (ATG) | Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR) | |
| Thymoglobuline Genzyme | Thymoglobuline Genzyme | University Hospital, Basel, Switzerland | marketed | Polyclonal antithymocyte globulin (ATG) | Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others) | |
| rabbit ATG(Sanofi/Genzyme) | rabbit ATG(Sanofi/Genzyme) | Chinese PLA General Hospital | marketed | Polyclonal antithymocyte globulin (ATG) | Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR, and others) | |
| Anti-human Thymoglobulin | Anti-human Thymoglobulin | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | marketed | Polyclonal antithymocyte globulin (ATG) | T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) | |
| Rabbit ATG, (Genzyme) | Rabbit ATG, (Genzyme) | Jinan Military General Hospital | marketed | Polyclonal antithymocyte globulin (ATG) | T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) | |
| ATG Fresenius | ATG Fresenius | University Hospital, Basel, Switzerland | marketed | Polyclonal antithymocyte globulin (ATG) | T-cell surface antigens (CD2, CD3, CD4, CD8, CD25, HLA-DR) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Polyclonal antithymocyte globulin (ATG) class)
- University Hospital, Basel, Switzerland · 2 drugs in this class
- Chinese PLA General Hospital · 1 drug in this class
- Cooperative Study Group A for Hematology · 1 drug in this class
- Jinan Military General Hospital · 1 drug in this class
- M.D. Anderson Cancer Center · 1 drug in this class
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Flu-ATG CI watch — RSS
- Flu-ATG CI watch — Atom
- Flu-ATG CI watch — JSON
- Flu-ATG alone — RSS
- Whole Polyclonal antithymocyte globulin (ATG) class — RSS
Cite this brief
Drug Landscape (2026). Flu-ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/flu-atg. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab